| Literature DB >> 29242962 |
M M Holtsche1, D Zillikens2, E Schmidt2.
Abstract
Mucous membrane pemphigoid (MMP) is a pemphigoid disease defined by the presence of autoantibodies against the dermal-epidermal junction and predominant involvement of mucous membranes. Diagnosis is made by the clinical presentation and linear deposits of IgG and/or IgA and/or C3 at the dermal-epidermal junction by direct immunofluorescence microscopy of a perilesional biopsy. Circulating autoantibodies can be detected in most patients by indirect immunofluorescence microscopy on salt-split human skin as well as ELISA and immunoblotting with recombinant and cell-derived target antigens. For systemic treatment of MMP, corticosteroids, dapsone, mycophenolates, and azathioprine are applied. In severe cases and in cases with rapid disease progression cyclophosphamide, rituximab, high-dose intravenous immunoglobulins, and immunoadsorption are used. For the successful management of MMP patients, close cooperation with dentists, ophthalmologists, ENT specialists, gynecologists, and gastroenterologists is essential.Entities:
Keywords: Autoantibodies; Basal membrane zone; Immunofluorescence; Immunosuppression; Mucous membrane erosions
Mesh:
Substances:
Year: 2018 PMID: 29242962 DOI: 10.1007/s00105-017-4089-y
Source DB: PubMed Journal: Hautarzt ISSN: 0017-8470 Impact factor: 0.751